TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) is now available.
Jiangsu Recbio Technology Co., Ltd. announced its unaudited interim results for the first half of 2025, highlighting significant progress in its vaccine development pipeline. The company is advancing its phase III clinical trials for its HPV 9-valent vaccine and shingles vaccine, with promising safety and efficacy results. However, due to low global demand, the company has decided not to pursue further clinical development of its COVID-19 vaccine, instead focusing on future respiratory combination vaccines and monitoring mRNA vaccine technology.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of vaccines. The company is involved in the research and development of vaccines for diseases such as HPV, shingles, respiratory syncytial virus, and COVID-19.
Average Trading Volume: 134,086
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.78B
See more data about 2179 stock on TipRanks’ Stock Analysis page.